NICE has recommended routine NHS access to nusinersen and risdiplam for spinal muscular atrophy, ending time-limited managed access schemes in place since 2019. Medscape News UK Source link : https://www.medscape.com/viewarticle/two-sma-drugs-move-routine-nhs-funding-2026a1000fnk?src=rss...
Read more









